Bitcoin trades near $91,500 after failing to hold $92K as RSI drops below 60, putting focus on trend strength and the risk of a cycle shift.Bitcoin trades near $91,500 after failing to hold $92K as RSI drops below 60, putting focus on trend strength and the risk of a cycle shift.

Bitcoin’s RSI Flashes Warning Signs as Price Stalls Below $92K

Bitcoin (BTC) is trading around $91,500 after failing to hold above the $92,000 level earlier today. The asset has posted a minor daily gain but is down 1% over the past week.

Analysts are now watching technical signals, especially the RSI, which has dropped below a level that often reflects strength in trend cycles.

RSI Drops Below 60, Trend at Risk

The monthly Relative Strength Index (RSI) has slipped under 60, raising questions about the current phase of the cycle. Analyst Egrag Crypto expected it to stay above that level, saying,

While the RSI is starting to curve upward, momentum remains uncertain. Egrag noted that reclaiming 60 could bring the bull cycle back into play. If not, the structure may shift toward deeper consolidation, with the next RSI support around 38.

$92K Still Capping Bitcoin Price Action

Bitcoin briefly reached $92,400 on Monday, but soon withdrew. That action was short-lived, and it coincided with the resurgence of tension between US President Trump and Federal Reserve Chair Powell. Since then, BTC has fallen back under the threshold of $92,000.

The $92,000 level remains a key hurdle. Until the asset breaks and holds above it, the chance of a return to the yearly open price increases. Prior analysis also pointed to a possible move toward $70,000 if downside pressure builds in the weeks ahead.

Moreover, Bitcoin continues to trade above a short-term ascending trendline and the 21-day moving average. This structure is helping the price hold its ground near $90,000. Michaël van de Poppe noted,

The $94,000 level is the next clear resistance. A break above that may open the way toward $100,400 and higher zones. Below current levels, a breakdown would weaken the bullish setup.

Price Range Limits Momentum for Now

Crypto analyst CryptosBatman described BTC’s current move as stuck inside a weekly inside bar pattern. He explained,

Daan Crypto Trades pointed out that Q1 often brings stronger price action for Bitcoin. He noted, “The last time it did awful was in 2018… Q1 does tend to be quite good, especially in recent years.” Traders remain focused on whether BTC can hold above support or if another leg lower is next.

The post Bitcoin’s RSI Flashes Warning Signs as Price Stalls Below $92K appeared first on CryptoPotato.

Market Opportunity
NEAR Logo
NEAR Price(NEAR)
$1.718
$1.718$1.718
-1.60%
USD
NEAR (NEAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23